Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07322718
EARLY_PHASE1

Safety and Efficacy Study of RXIM002 in Severe, Relapsed or Refractory Autoimmune Diseases

Sponsor: Ruijin Hospital

View on ClinicalTrials.gov

Summary

This Phase 1, open-label study evaluates the safety, tolerability, and preliminary efficacy of RXIM002, a CD19-targeting circular RNA-mediated in-vivo CAR T-cell therapy, in adults with severe, relapsed, or refractory B cell-mediated autoimmune diseases.

Official title: A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the CD19-Targeting Circular RNA Product RXIM002 in Patients With Relapsed or Refractory B Cell-Mediated Autoimmune Diseases

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

27

Start Date

2025-12-24

Completion Date

2028-03-19

Last Updated

2026-01-23

Healthy Volunteers

No

Interventions

BIOLOGICAL

RXIM002 product

Prior to infusion of the RXIM002 product, subjects will receive pre-medication if needed

Locations (1)

Ruijin Hospital

Shanghai, Huangpu District, China